Allergies Development In-Vitro In-Vivo 
Drug Discovery World
JUNE 26, 2023
IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. The post Could a monoclonal antibody treat peanut allergy?
The Pharma Data
JANUARY 12, 2021
Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Dr. Graham earned an M.D.,
The Pharma Data
OCTOBER 22, 2020
The speed and rigor with which Veklury has been developed and approved in the U.S. Previously authorized by the FDA for emergency use to treat COVID-19, Veklury is now the first and only approved COVID-19 treatment in the United States.
Expert insights. Personalized for you.
52 
Let's personalize your content